Literature DB >> 16426913

Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.

Stefan Denzinger1, Kristin Mohren, Ruth Knuechel, Peter J Wild, Maximilian Burger, Wolf F Wieland, Arndt Hartmann, Robert Stoehr.   

Abstract

The clonality status of multifocal bladder tumors is still controversially discussed with experimental evidence for both monoclonality and field cancerization. Methodologically, loss of heterozygosity (LOH) and genomic sequencing analyses are widely used in clonality analysis of malignant tumors. In the present study, we used LOH analysis and genomic sequencing in combination with fluorescence in situ hybridization (FISH) and extensive histopathologic whole-organ mapping to determine the clonal relationship of multifocal bladder cancer disease. Tissue sections (1 cm(2)) covering the entire urothelial lining were systematically dissected from 2 cystectomy specimens (cystectomy 1, no urothelial lesions, bladder infiltration by a leiomyosarcoma of the vaginal wall; cystectomy 2, multifocal pT3G3 tumors). The location of each sample was documented (bladder mapping). Urothelial cells were microdissected for LOH (chromosomes 9, 17p) and FISH analysis (CDKI2 (9p21), FACC (9q22), p53 (17p13.1), and centromeric probes for corresponding chromosome). Exons 5 to 9 of the p53 gene were sequenced in all tumor samples. No chromosomal alterations were detected in the cystectomy specimen without urothelial malignancies. The tumor-bearing bladder showed an increasing frequency of deletions with increasing malignancy of the investigated lesions. LOH analysis detected deletions only on chromosomes 9p and 17p. In contrast, FISH analysis revealed deletions of all investigated genes at chromosomes 9p, 9q, and 17p in all samples analyzed (preneoplastic and neoplastic tissue). An identical p53 mutation in codon 281 was found in all 7 analyzable tumor samples. Combination of molecular data with histopathologic bladder mapping suggested a monoclonal development of the multifocal lesions mostly via intraurothelial migration. Our data strengthen the results from recently published studies that patients with advanced urothelial carcinoma seem to have a monoclonal panurothelial disease in most cases. FISH showed a much higher sensitivity for detection of chromosomal losses than classical LOH analysis, especially in preneoplastic and small lesions. Combining 3 molecular approaches together with histopathologic organ mapping presents a valuable tool to determine the clonality status of multifocal bladder tumors.

Entities:  

Mesh:

Year:  2005        PMID: 16426913     DOI: 10.1016/j.humpath.2005.10.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

1.  [Interdisciplinary networking for clinical and molecular questions in non-muscle invasive urothelial carcinoma of the bladder].

Authors:  S Denzinger; A Hartmann; F Hofstaedter; R Knuechel; P J Wild; D Zaak; C Stief; W F Wieland; R Stoehr; M Burger
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Production of urothelium from pluripotent stem cells for regenerative applications.

Authors:  Stephanie L Osborn; Eric A Kurzrock
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

3.  Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.

Authors:  Peng Huang; Jie Chen; Lei Wang; Yanqun Na; Haruki Kaku; Hideo Ueki; Katsumi Sasaki; Ken Yamaguchi; Kai Zhang; Takashi Saika; Yasutomo Nasu; Masami Watanabe; Hiromi Kumon
Journal:  Med Oncol       Date:  2011-05-01       Impact factor: 3.064

4.  Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.

Authors:  Joshua I Warrick; Daniel H Hovelson; Anmol Amin; Chia-Jen Liu; Andi K Cani; Andrew S McDaniel; Venkata Yadati; Michael J Quist; Alon Z Weizer; J Chad Brenner; Felix Y Feng; Rohit Mehra; Catherine S Grasso; Scott A Tomlins
Journal:  Virchows Arch       Date:  2014-12-11       Impact factor: 4.064

Review 5.  Passenger mutations as a marker of clonal cell lineages in emerging neoplasia.

Authors:  Jesse J Salk; Marshall S Horwitz
Journal:  Semin Cancer Biol       Date:  2010-10-15       Impact factor: 15.707

Review 6.  Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.

Authors:  Georgios Gakis; Peter C Black; Bernard H Bochner; Stephen A Boorjian; Arnulf Stenzl; George N Thalmann; Wassim Kassouf
Journal:  Eur Urol       Date:  2016-10-06       Impact factor: 20.096

Review 7.  Tissue engineering for the oncologic urinary bladder.

Authors:  Tomasz Drewa; Jan Adamowicz; Arun Sharma
Journal:  Nat Rev Urol       Date:  2012-08-21       Impact factor: 14.432

8.  Evaluating the expression of oct4 as a prognostic tumor marker in bladder cancer.

Authors:  Nasim Hatefi; Nazila Nouraee; Mahmoud Parvin; Seyed-Amir Mohsen Ziaee; Seyed Javad Mowla
Journal:  Iran J Basic Med Sci       Date:  2012-11       Impact factor: 2.699

9.  Clinical significance of CD24 as a predictor of bladder cancer recurrence.

Authors:  Chunxiao Liu; Shaobo Zheng; Haiyan Shen; Kai Xu; Jie Chen; Hulin Li; Yawen Xu; Abai Xu; Binshen Chen; Haruki Kaku; Yasutomo Nasu; Hiromi Kumon; Peng Huang; Masami Watanabe
Journal:  Oncol Lett       Date:  2013-05-21       Impact factor: 2.967

10.  Clinical implications and utility of field cancerization.

Authors:  Gabriel D Dakubo; John P Jakupciak; Mark A Birch-Machin; Ryan L Parr
Journal:  Cancer Cell Int       Date:  2007-03-15       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.